Cefoxitin and cefamandole were evaluated in vitro against 263 Several cephalosporin antibiotics currently are available for the therapy of infection. Two more recently studied compounds, cefoxitin and cefamandole, by virtue of their apparent resistance to degradation by cephalosporinase enzymes, are reported to extend the antibacterial spectrum of the cepahlosporin antibiotics (2-6). Cefoxitin, although resembling cephalothin structurally, is actually a member of the cephamycin group of antibiotics (11). The present studies were performed to assess the in vitro antibacterial activity of cefoxitin and cefamandole.
Several cephalosporin antibiotics currently are available for the therapy of infection. Two more recently studied compounds, cefoxitin and cefamandole, by virtue of their apparent resistance to degradation by cephalosporinase enzymes, are reported to extend the antibacterial spectrum of the cepahlosporin antibiotics (2-6). Cefoxitin, although resembling cephalothin structurally, is actually a member of the cephamycin group of antibiotics (11). The present studies were performed to assess the in vitro antibacterial activity of cefoxitin and cefamandole.
MATERIALS AND METHODS Antibacterial activity was determined by antibiotic dilution methods performed in nutrient (Difco) broth (NB) and agar and Mueller-Hinton (Difco) broth (MHB) and agar. Studies in agar were performed by use of a Steers replicator device (8) . In broth both minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations (MBC) were determined by methods described previously from this laboratory (7, 10) . The MBC was defined as the lowest concentration of antibiotic in which fewer than three viable colonies were recovered when about 0 bacteriaceae tested in broth medium with two inoculum sizes of bacterial cells. In MHB the MICs obtained when the lower inoculum size was employed were nearly comparable to those obtained in agar. In addition, when studied in MHB, 20 ug of cefoxitin/ml was bactericidal against all isolates of E. coli and killed 28 of 30 strains of P. mirabilis even when tested though 20 ug of cefoxitin/ml was bactericidal against 80% of isolates of indole-positive Proteus strains when the lower inoculum size was employed, only 47% of strains were killed at the higher inoculum. Cefoxitin showed negligible activity in MHB against isolates of Enterobacter, and most isolates grew in concentrations of 250 ,g of antibiotic/ml. Results obtained using NB were similar to those obtained with MHB, except that cefoxitin appeared to exert less bactericidal activity against some genera in NB than in MHB.
Cefoxitin at 20 ug or less/ml inhibited and killed all 30 isolates of S. aureus in both broth media when tested against the lower inoculum of bacterial cells (data not shown). However, in MHB 14% of these isolates resisted killing when the higher inoculum size was tested. No isolate of P. aeruginosa was inhibited by cefoxitin even at a concentration of 250 ,ug/ml. Cefoxitin exerted some activity against the enterococcus, but the majority of isolates grew in concentrations of 100 ,g/ml.
In agar, all four of the cephalothin-resistant isolates of E. coli were susceptible to 20 ug or less of cefoxitin/ml, and three of the four isolates were killed in broth at 20 ,g of cefoxitin/ ml, even when tested against the higher inoculum of bacterial cells.
Fifty-three isolates ofEnterobacter were speciated into five subgroups, e.g., E. hafnia (four isolates). E. liquefaciens (five isolates), E. agglomerans (four isolates), E. cloacae (twentyseven isolates), and E. aerogenes (thirteen isolates). In general, isolates of E. hafnia were more sensitive to cefoxitin than the other four species. In broth, 10 ug of cefoxitin/ml killed all four isolates of E. hafnia, whereas none of the other species was inhibited or killed until concentrations of at least 50 ,ug/ml were achieved.
Cefamandole. The activity of cefamandole against 173 isolates of Enterobacteriaceae tested in agar medium is summarized in Fig. 4 . At 20 ug of cefamandole/ml all 30 isolates each of E. coli, P. mirabilis, and Klebsiella were inhibited in both agar media regardless of the size of the inoculum. In addition, approximately 75% of 30 isolates of indole-positive Proteus strains and 60% of 53 isolates ofEnterobacter also were susceptible to 20 ug or less of cefamandole/ml in agar.
The results of testing these same isolates with cefamandole in broth are summarized in Fig. 5 and 6 , which also depict the effects of medium and inoculum size on the MIC and MBC. In MHB medium cefamandole showed much less activity against isolates of Enterobacter and indole-positive Proteus species than was demonstrated in agar. This discrepancy was most apparent when the MBC was determined against a high inoculum of bacterial cells. Although the results obtained with cefamandole were similar in both broth media, there was less bactericidal activity against Klebsiella and P. mirabilis in NB than in MHB.
Cefamandole at 10 cidal against all 30 isolates of S. aureus in NB at both inoculum sizes of bacterial cells (data not shown). When tested against the high inoculum size in MHB, 28 of the 30 strains were killed by 10 ug of cefamandole or less/ml. Similar to cefoxitin, cefamandole was completely inactive against P. aeruginosa. However, cefamandole was somewhat more active against the enterococcus. For example, when the lower inoculum size of bacterial cells was tested in broth, 50 ,ug of cefamandole or less/ml killed 80% of the isolates. On the other hand, 20 ,ug/ ml was rarely bactericidal.
The cephalothin-resistant isolates of E. coli showed variable susceptibility to cefamandole. For example, in broth medium, 20 ,ug of cefamandole/ml inhibited only one of the four cultures.
Isolates of E. aerogenes were more sensitive to cefamandole than were the other species of Enterobacter, and all 13 strains were inhibited and killed by 20 ug of cefamandole or less/ml. On the other hand, only 25% of the other species of Enterobacter were susceptible to that concentration of cefamandole in broth.
DISCUSSION
It appears that at attainable serum levels (20 ,ug/ml) both cefoxitin and cefamandole are active against the majority of E. coli, P. mirabilis, Klebsiella, and Staphylococcus aureus strains. Although cefoxitin and, to a lesser degree, cefamandole are less active in vitro against S. aureus than other currently available cephalosporins, this is unlikely to be a clinical problem. In addition, similar to other cephalosporins, cefoxitin and cefamandole were inactive against all isolates ofP. aeruginosa. Cefamandole appeared somewhat more active against enterococci than other clinically available cephalosporins.
Unlike the cephalosporins, cefoxitin demonstrated appreciable activity in both agar and broth medium against indole-positive Proteus species. Moreover, cefoxitin was active against four clinical isolates of cephalothin-resistant E. coli. This enhanced activity of cefoxitin may be related to its apparent resistance to degradation by beta-lactamase, a characteristic of the cephamycins (6) . Cefoxitin also has been reported to be active in vitro against strains of Bacteroides fragilis and Serratia (4, 9) .
In contrast to cefoxitin, the primary in vitro advantage of cefamandole appeared to be its activity against some strains of Enterobacter. However, against most of these strains, the activity of cefamandole was demonstrated in agar but not in broth. Cefamandole also has been reported to be more active than other cephalosporins against Haemophilus influenzae (3) . This enhanced activity also may be related to better stability of cefamandole against certain cephalosporinase-degrading enzymes. The reasons for the differences observed in the susceptibility of some strains of organisms to cefamandole when tested in broth are unclear. Both cefoxitin and cefamandole appear stable in MHB and NB, and simple degradation of the antibiotics is unlikely to account for the differences. Since in our studies we did not measure residual antibiotic after addition of microorganisms, we are unable to comment on the possibility of enzymatic inactivation of cefamandole when tested against a high inoculum size of bacterial cells in broth.
In conclusion, cefoxitin and cefamandole possess some in vitro characteristics that may provide some advantages over the currently available cephalosporin compounds. The results of ongoing clinical trials hopefully will define these specific attributes. 
